MEGACE

This brand name is authorized in Croatia, Cyprus, France, Ireland, Italy, Lithuania, Poland, Singapore, Tunisia, Turkey, UK.

Active ingredients

The drug MEGACE contains one active pharmaceutical ingredient (API):

1	Megestrol UNII TJ2M0FR8ES - MEGESTROL ACETATE
	Megestrol possesses pharmacological properties similar to those of natural progesterone. Megestrol acetate is a potent progestogen that exerts significant anti-oestrogenic effects. It has no androgenic or oestrogenic properties.
	Read more about Megestrol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEGACE Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AB01	Megestrol	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AB Progestogens
Discover more medicines within L02AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	67448384
GB	Medicines & Healthcare Products Regulatory Agency	144902, 27007
HR	Agencija za lijekove i medicinske proizvode	HR-H-977775077
IE	Health Products Regulatory Authority	33453, 33472, 33575, 33579, 62896
IT	Agenzia del Farmaco	027597020
LT	Valstybinė vaistų kontrolės tarnyba	1003571, 1069901, 1078642, 1079763, 1079990
PL	Rejestru Produktów Leczniczych	100088894
SG	Health Sciences Authority	06701P
TN	Direction de la Pharmacie et du Médicament	5253081H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699525016713